Morin et al — CBT-I vs medication for chronic insomnia
Morin, C. M., Vallières, A., Guay, B., Ivers, H., Savard, J., Mérette, C., Bastien, C. & Baillargeon, L.
What this study found
CBT-I and zolpidem worked roughly equivalently at six weeks. At twelve months, CBT-I gains were maintained while medication gains largely weren't. The single most-cited piece of evidence behind every major guideline recommending CBT-I as first-line for chronic insomnia.
What they did
160 adults with chronic insomnia were randomised to one of four treatment arms:
- CBT-I alone (6 weeks of structured therapy)
- Zolpidem alone (a prescription sleep medication)
- Combined CBT-I + zolpidem
- Placebo
Outcomes were measured at the end of the acute treatment phase (6 weeks), and again at 6 and 12 months follow-up. Primary outcomes included sleep onset latency, total sleep time, sleep efficiency, and insomnia severity scores.
Key findings
- 1
At 6 weeks, all three active treatments produced significant improvement over placebo. CBT-I alone and zolpidem alone were roughly equivalent. Combined treatment was modestly best.
- 2
At 6 months, the divergence began. CBT-I patients largely maintained their gains. Zolpidem-alone patients showed substantial regression toward baseline.
- 3
At 12 months, the divergence was stark. ~60% of CBT-I patients remained in remission. ~30% of zolpidem-alone patients did.
- 4
Combined treatment at 12 months performed similarly to CBT-I alone — adding medication didn't add to long-term outcomes.
- 5
Adverse events were almost exclusively in the medication arms (next-day grogginess, headache, GI symptoms). CBT-I had no significant side effects.
What it means for you
If you have chronic insomnia, CBT-I is the treatment with the strongest long-term evidence. Sleep medication has a place — primarily short-term, as a bridge or for crisis management — but it isn't the right long-term treatment for chronic insomnia. Every major guideline (American Academy of Sleep Medicine, NICE, European Sleep Research Society) recommends CBT-I first, with medication considered only when CBT-I is unavailable or has failed.
See CBT-I explained for the practical guide to what CBT-I actually involves.
Caveats
- Trial was face-to-face CBT-I delivered by trained therapists. App-based and self-guided versions are effective but typically show somewhat smaller effect sizes.
- Participants had insomnia without significant co-occurring depression or other psychiatric conditions. Effects in comorbid populations may differ.
- 12 months is a meaningful follow-up but not lifetime. Some studies suggest even longer-term durability of CBT-I gains; others find some slippage.
- Zolpidem is one specific medication. Other sleep medications (eszopiclone, suvorexant) may have different long-term profiles.
Source
Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia: a randomized controlled trial · JAMA · 2009PMID 19454639